Loading…
DOK 7 gene therapy enhances motor activity and life span in ALS model mice
Amyotrophic lateral sclerosis ( ALS ) is a progressive, multifactorial motor neurodegenerative disease with severe muscle atrophy. The glutamate release inhibitor riluzole is the only medication approved by the FDA , and prolongs patient life span by a few months, testifying to a strong need for new...
Saved in:
Published in: | EMBO molecular medicine 2017-07, Vol.9 (7), p.880-889 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Amyotrophic lateral sclerosis (
ALS
) is a progressive, multifactorial motor neurodegenerative disease with severe muscle atrophy. The glutamate release inhibitor riluzole is the only medication approved by the
FDA
, and prolongs patient life span by a few months, testifying to a strong need for new treatment strategies. In
ALS
, motor neuron degeneration first becomes evident at the motor nerve terminals in neuromuscular junctions (
NMJ
s), the cholinergic synapse between motor neuron and skeletal muscle; degeneration then progresses proximally, implicating the
NMJ
as a therapeutic target. We previously demonstrated that activation of muscle‐specific kinase Mu
SK
by the cytoplasmic protein Dok‐7 is essential for
NMJ
formation, and forced expression of Dok‐7 in muscle activates Mu
SK
and enlarges
NMJ
s. Here, we show that therapeutic administration of an adeno‐associated virus vector encoding the human
DOK
7
gene suppressed motor nerve terminal degeneration at
NMJ
s together with muscle atrophy in the
SOD
1‐G93A
ALS
mouse model. Ultimately, we show that
DOK
7
gene therapy enhanced motor activity and life span in
ALS
model mice.
image
Forced expression of
DOK
7
in muscle enlarges the neuromuscular junction (
NMJ
). Here,
DOK
7
gene therapy suppresses
NMJ
degeneration and enhances motor activity and life span in a mouse model of
ALS
, a progressive motor neurodegenerative disease.
DOK
7
gene therapy suppresses motor nerve terminal degeneration at the neuromuscular junction (
NMJ
) and muscle atrophy in
ALS
model mice.
DOK
7
gene therapy prolongs lifespan and enhances motor activity in
ALS
model mice.
DOK
7
gene therapy, or any equivalent method that stably and safely enlarges the
NMJ
, has potential for treating various motor neuron diseases that manifest
NMJ
defects. |
---|---|
ISSN: | 1757-4676 1757-4684 |
DOI: | 10.15252/emmm.201607298 |